Literature DB >> 353924

Laboratory trials with inactivated vaccines against Escherichia coli (O2:K1) infection in fowls.

J R Deb, E G Harry.   

Abstract

Laboratory trials were carried out with an O2:K1 vaccine prepared with either the Freund's complete or incomplete adjuvant. Both types of vaccine administered subcutaneously were highly effective against a challenge with the vaccine strain within three to four weeks after vaccination at two to three weeks of age. The complete adjuvant vaccine was more effective than the incomplete adjuvant vaccine when administered to chickens of an earlier age, and in the rate of development and duration of immunity. The efficacy of both vaccines was unimpaired by their incorporation with the Newcastle disease oil adjuvant (inactivated) vaccine (Newcadin). The use of an oil adjuvant vaccine was not found to affect the rate of growth adversely or to produce any other reaction prejudicial to its commerical application. The efficacy of the vaccines was unimpaired by their incorporation with Newcastle disease oil adjuvant (inactivated) vaccine (Newcadin) thus demonstrating the possibility of producing a combined Escherichia coli/Newcastle disease virus vaccine.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 353924

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  4 in total

1.  Outer membrane protein patterns mark clones of Escherichia coli O2 and O78 strains that cause avian septicemia.

Authors:  V Kapur; D G White; R A Wilson; T S Whittam
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

2.  Identification of minimal predictors of avian pathogenic Escherichia coli virulence for use as a rapid diagnostic tool.

Authors:  Timothy J Johnson; Yvonne Wannemuehler; Curt Doetkott; Sara J Johnson; Sandra C Rosenberger; Lisa K Nolan
Journal:  J Clin Microbiol       Date:  2008-10-08       Impact factor: 5.948

3.  A carAB mutant of avian pathogenic Escherichia coli serogroup O2 is attenuated and effective as a live oral vaccine against colibacillosis in turkeys.

Authors:  J K Kwaga; B J Allan; J V van der Hurk; H Seida; A A Potter
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

4.  Immune responses associated with homologous protection conferred by commercial vaccines for control of avian pathogenic Escherichia coli in turkeys.

Authors:  Jean-Rémy Sadeyen; Zhiguang Wu; Holly Davies; Pauline M van Diemen; Anita Milicic; Roberto M La Ragione; Pete Kaiser; Mark P Stevens; Francis Dziva
Journal:  Vet Res       Date:  2015-01-23       Impact factor: 3.683

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.